{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T21:27:36Z","timestamp":1794605256040,"version":"4.9.1"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.ygyno.2024.10.015","type":"journal-article","created":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T18:38:12Z","timestamp":1729622292000},"page":"194-200","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Cold ischemia time and formalin fixation time in endometrial cancer: Should breast cancer guidelines for preanalytical variables be applied to hysterectomy specimens?"],"prefix":"10.1016","volume":"191","author":[{"given":"Paulina J.","family":"Haight","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sydney","family":"Lammers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quinn","family":"Kistenfeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsea","family":"Leipold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian A.","family":"Suarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary H.","family":"Tozbikian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwini","family":"Esnakula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casey","family":"Cosgrove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin L.","family":"Bixel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ygyno.2024.10.015_bb0200","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"2","key":"10.1016\/j.ygyno.2024.10.015_bb0030","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ygyno.2014.05.018","article-title":"Endometrial cancer: a review and current management strategies: part I","volume":"134","author":"Burke","year":"2014","journal-title":"Gynecol. Oncol."},{"issue":"9","key":"10.1016\/j.ygyno.2024.10.015_bb0065","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1080\/14737140.2018.1491311","article-title":"Management strategies for recurrent endometrial cancer","volume":"18","author":"Connor","year":"2018","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.ygyno.2024.10.015_bb0060","series-title":"Precision Surgical Oncology?","author":"Compton","year":"2018"},{"key":"10.1016\/j.ygyno.2024.10.015_bb0130","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"The Cancer genome atlas research network. Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Levine","year":"2013","journal-title":"Nature"},{"issue":"33","key":"10.1016\/j.ygyno.2024.10.015_bb0150","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1200\/JCO.20.01076","article-title":"Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a phase III trial (NRG oncology\/ GOG0209)","volume":"38","author":"Miller","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2024.10.015_bb0190","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.gore.2019.04.002","article-title":"Retreatment with carboplatin and paclitaxel for recurrent endometrial cancer: a retrospective study of the memorial Sloan Kettering Cancer center experience","volume":"28","author":"Rubinstein","year":"2019","journal-title":"Gynecol Oncol Rep."},{"key":"10.1016\/j.ygyno.2024.10.015_bb0160","series-title":"NCCN Clinical Practice Guidelines in Oncology. Uterine Neoplasms Version 2.2024","author":"National Comprehensive Cancer Network (NCCN)","year":"2024"},{"key":"10.1016\/j.ygyno.2024.10.015_bb0055","article-title":"Template for reporting results of biomarker testing of specimens from patients with carcinoma of the endometrium. Version: endometrium","volume":"1.2.0.1","author":"College of American Pathologists","year":"2019","journal-title":"Biomarkers"},{"key":"10.1016\/j.ygyno.2024.10.015_bb0075","series-title":"College of American Pathologists: Template for reporting results of biomarker testing of specimens from patients with carcinoma of gynecologic origin, version 1.1.0.0","author":"Crothers","year":"2023"},{"key":"10.1016\/j.ygyno.2024.10.015_bb0100","article-title":"Pre-analytical variation: the leading cause of error in laboratory medicine","author":"Ghaedi","year":"2016","journal-title":"Am. Assoc. Clin. Chem.: Clin. Lab. News."},{"issue":"2","key":"10.1016\/j.ygyno.2024.10.015_bb0010","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/00129039-200206000-00015","article-title":"Effect of prolonged formalin fixation time on the immunohistochemical reactivity of breast markers","volume":"10","author":"Arber","year":"2002","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"issue":"11","key":"10.1016\/j.ygyno.2024.10.015_bb0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0079901","article-title":"Comparison of HER2 and phosphor-HER2 expression between biopsy and resected breast cancer specimens using a quantitative assessment method","volume":"8","author":"Bai","year":"2013","journal-title":"PloS One"},{"issue":"6","key":"10.1016\/j.ygyno.2024.10.015_bb0120","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1097\/PAI.0b013e318248bf6d","article-title":"Delay to formalin fixation alters morphology and immunohistochemistry for breast carcinoma","volume":"20","author":"Khoury","year":"2012","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"issue":"1","key":"10.1016\/j.ygyno.2024.10.015_bb0135","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/modpathol.2012.135","article-title":"The effect of prolonged cold ischemia time on estrogen receptor immunohistochemistry in breast cancer","volume":"26","author":"Li","year":"2013","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ygyno.2024.10.015_bb0170","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/947041","article-title":"The effect of cold ischemia time and\/or formalin fixation on estrogen receptor, progesterone receptor, and human epidermal growth factor receptor-2 results in breast carcinoma","author":"Pekmezci","year":"2012","journal-title":"Patholog. Res. Int."},{"issue":"5","key":"10.1016\/j.ygyno.2024.10.015_bb0175","doi-asserted-by":"crossref","first-page":"R76","DOI":"10.1186\/bcr2719","article-title":"Extreme loss of immunoreactive p-Akt and p-Erk1\/2 during routine fixation of primary breast cancer","volume":"12","author":"Pinhel","year":"2010","journal-title":"Breast Cancer Res."},{"issue":"8","key":"10.1016\/j.ygyno.2024.10.015_bb0230","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1038\/modpathol.2012.59","article-title":"The effect of cold ischemic time on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast carcinoma","volume":"25","author":"Yildiz-Aktas","year":"2012","journal-title":"Mod. Pathol."},{"issue":"9793","key":"10.1016\/j.ygyno.2024.10.015_bb0080","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","article-title":"Early breast Cancer Trialists' collaborative group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomized trials","volume":"378","year":"2011","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ygyno.2024.10.015_bb0095","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1200\/JCO.19.01455","article-title":"NSABP B-47\/NRG oncology phase III randomized trial comparing adjuvant chemotherapy with or without Trastuzumab in high-risk invasive breast Cancer negative for HER2 by FISH and with IHC 1+ or 2","volume":"38","author":"Fehrenbacher","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.ygyno.2024.10.015_bb0105","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.5858\/134.7.e48","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version)","volume":"134","author":"Hammond","year":"2010","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"1","key":"10.1016\/j.ygyno.2024.10.015_bb0225","doi-asserted-by":"crossref","first-page":"18","DOI":"10.5858\/2007-131-18-ASOCCO","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer","volume":"131","author":"Wolf","year":"2007","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.ygyno.2024.10.015_bb0180","article-title":"Human epidermal growth factor receptor 2 (Her2) testing for uterine serous carcinoma: report of scenarios of unusual overexpression","volume":"32","author":"Quddus","year":"2020","journal-title":"Gynecol Oncol Reports."},{"issue":"3","key":"10.1016\/j.ygyno.2024.10.015_bb0185","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/PGP.0000000000000690","article-title":"Does specimen type have an impact on HER2 status in endometrial serous carcinoma? Discordant HER2 status of paired endometrial biopsy and hysterectomy specimens in the presence of frequent Intratumoral heterogeneity","volume":"40","author":"Rottmann","year":"2021","journal-title":"Int. J. Gynecol. Pathol."},{"issue":"12","key":"10.1016\/j.ygyno.2024.10.015_bb0025","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.5858\/arpa.2016-0331-CP","article-title":"HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology","volume":"140","author":"Bartley","year":"2016","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"23","key":"10.1016\/j.ygyno.2024.10.015_bb0085","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus chemotherapy in advanced endometrial cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"6349","key":"10.1016\/j.ygyno.2024.10.015_bb0125","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.ygyno.2024.10.015_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of Pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient Cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.ygyno.2024.10.015_bb0155","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ygyno.2024.10.015_bb0015","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.ygyno.2016.03.006","article-title":"Estrogen receptor-alpha as a predictive biomarker in endometrioid endometrial cancer","volume":"141","author":"Backes","year":"2016","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2024.10.015_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2022.100085","article-title":"Grade and estrogen receptor expression identify a subset of no specific molecular profile endometrial carcinomas at a very low risk of disease-specific death","volume":"36","author":"Jamieson","year":"2023","journal-title":"Mod. Pathol."},{"issue":"4","key":"10.1016\/j.ygyno.2024.10.015_bb0210","doi-asserted-by":"crossref","first-page":"407.e1","DOI":"10.1016\/j.ajog.2021.05.007","article-title":"Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer","volume":"225","author":"Van Weelden","year":"2021","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"7","key":"10.1016\/j.ygyno.2024.10.015_bb0215","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/s41416-023-02141-0","article-title":"Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry","volume":"128","author":"Vermij","year":"2023","journal-title":"Br. J. Cancer"},{"issue":"20","key":"10.1016\/j.ygyno.2024.10.015_bb0090","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1200\/JCO.2017.76.5966","article-title":"Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2\/neu","volume":"36","author":"Fader","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2024.10.015_bb0145","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of Trastuzumab Deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2024.10.015_bb0005","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1309\/AJCPB1RIT5YXMRIS","article-title":"The effect of delay in fixation, different fixatives, and duration of fixation in estrogen and progesterone receptor results in breast carcinoma","volume":"135","author":"Apple","year":"2011","journal-title":"Am. J. Clin. Pathol."},{"issue":"4","key":"10.1016\/j.ygyno.2024.10.015_bb0110","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1309\/AJCPAIJPSN4A9MJI","article-title":"Fixation time does not affect expression of HER2\/neu: a pilot study","volume":"134","author":"Ibarra","year":"2010","journal-title":"Am. J. Clin. Pathol."},{"issue":"23","key":"10.1016\/j.ygyno.2024.10.015_bb0165","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1093\/jnci\/djs438","article-title":"Quantitative assessment of effect of preanalytic cold ischemic time on protein expression in breast cancer tissues","volume":"104","author":"Neumeister","year":"2012","journal-title":"J. Natl. Cancer Inst."},{"issue":"4","key":"10.1016\/j.ygyno.2024.10.015_bb0205","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/cncr.21650","article-title":"Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia","volume":"106","author":"Trimble","year":"2006","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2024.10.015_bb0040","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.ygyno.2018.04.005","article-title":"Immunohistochemistry for mismatch repair protein deficiency in endometrioid endometrial carcinoma yields equivalent results when performed on endometrial biopsy\/curettage or hysterectomy specimens","volume":"149","author":"Chapel","year":"2018","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2024.10.015_bb0035","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1055\/s-0033-1348896","article-title":"Racial and ethnic differences in the pathogenesis and clinical manifestations of uterine leiomyoma","volume":"31","author":"Catherino","year":"2013","journal-title":"Semin. Reprod. Med."},{"issue":"6","key":"10.1016\/j.ygyno.2024.10.015_bb0045","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1001\/jamaoncol.2022.0009","article-title":"Racial and ethnic differences in hysterectomy-corrected uterine corpus cancer mortality by stage and histologic subtype","volume":"8","author":"Clarke","year":"2022","journal-title":"JAMA Oncol."},{"issue":"22","key":"10.1016\/j.ygyno.2024.10.015_bb0050","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1200\/JCO.19.00151","article-title":"Hysterectomy-corrected uterine corpus cancer incidence trends and differences in relative survival reveal racial disparities and rising rates of nonendometrioid cancers","volume":"37","author":"Clarke","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2024.10.015_bb0070","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.ygyno.2017.03.017","article-title":"Surgical-pathological findings in type 1 and 2 endometrial cancer: an NRG oncology\/gynecologic oncology group study on GOG-210 protocol","volume":"145","author":"Creasman","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.10.015_bb0220","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3389\/fonc.2019.00265","article-title":"A novel approach to preoperative risk stratification in endometrial cancer: the added value of immunohistochemical markers","volume":"9","author":"Weinberger","year":"2019","journal-title":"Front. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082582401165X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082582401165X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T01:53:15Z","timestamp":1733881995000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082582401165X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":45,"alternative-id":["S009082582401165X"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.10.015","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cold ischemia time and formalin fixation time in endometrial cancer: Should breast cancer guidelines for preanalytical variables be applied to hysterectomy specimens?","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.10.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}